Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

Neil Korman, Thierry Passeron, Kenneth Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Diamant Thaçi

Page s46

Poster PDF

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths

Page s47

Poster PDF

Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter

Page s48

Poster PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, Subhashis Banerjee

Page s49

Poster PDF

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

James Del Rosso, Scott Guenthner, Chih-ho Hong, John E Jett, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Stephen C Piscitelli

Page s50

Poster PDF

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials

Linda Stein Gold, Mark Lebwohl, Robert Bissonnette, Bruce Strober, Anna M Tallman, Philip M Brown, Stephen C Piscitelli, David S Rubenstein

Page s51

Poster PDF

Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

April W Armstrong, Robert Bissonnette, Philip M Brown, Anna M Tallman, Kim A Papp

Page s52

Poster PDF

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Linda Stein Gold, Christopher E Griffiths, Anna M Tallman, Philip M Brown, Mark Lebwohl

Page s53

Poster PDF

Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension

Zoe D Draelos, Matthew M Draelos, Morten Praestegaard

Page s54

Poster PDF

Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream Demonstrates High Efficacy and Convenience in Skin of Color Patients with Plaque Psoriasis

Valerie Callender, Susan Taylor, Fran Cook-Bolden

Page s55

Poster PDF

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States

Teri Greiling, Melodie Young, Robert C Higham, April W Armstrong

Page s56

Poster PDF

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

Laura K Ferris, April W Armstrong, James Del Rosso, Zoe D Draelos, Melinda Gooderham, Mark Lebwohl, Kim A Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C Higham, Patrick Burnett, David R Berk

Page s57

Poster PDF

Patient Perspectives on the Prevalence and Burden of Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States

April W Armstrong, Melodie Young, Melissa Seal, Robert Higham, Teri Greiling

Page s58

Poster PDF

Improving Patient Acceptability and Adherence in Psoriasis Treatment

Alyssa Curcio, Christina Kontzias, Steven R Feldman

Page s59

Poster PDF

Evaluating treatment choice among patients with moderate or severe psoriasis in the United States

April W Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi, Vardhaman Patel, David Davidson, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Dipen Patel, Lauren Seigel

Page s60

Poster PDF

Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis

April W Armstrong, Richard B Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniel R Junqueira, Tracy Westley, Renata Kisa, Carolin Daamen, Matthias Augustin

Page s61

Poster PDF

Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

April W Armstrong, Sang Hee Park, Viktor Chirikov, Pierre Nicolas, Wei-Jhih Wang, Matthew J Colombo, Vardhaman Patel

Page s62

Poster PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

April W Armstrong, Kim A Papp, Joe Zhuo, Brandon Becker, Yichen Zhong, Jennifer L Beaumont, Michael DeRosa, Renata M Kisa, Subhashis Banerjee, Bruce Strober

Page s63

Poster PDF

Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

Mark Lebwohl, April W Armstrong, Joseph F Merola, Alice B Gottlieb, Leah Davis, Braulio Gomez, Susanne Wiegratz, Nancy Cross, Bruce Strober

Page s64

Poster PDF

Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Jonathan Barker, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul

Page s65

Poster PDF

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Natalie Nunez Gomez, Diamant Thaçi

Page s66

Poster PDF

Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials

Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, Bruce Strober, Andreas Pinter, Jose-Manuel Carrascosa, Paolo Gisondi, Jonathan Bleier, Cynthia Madden, Delphine Deherder, Natalie Nunez Gomez, Richard B Warren

Page s67

Poster PDF

Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension

Diamant Thaçi, Ron Vender, Menno de Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B Gottlieb

Page s68

Poster PDF

Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)

A Blauvelt, KC Duffin, N Magnolo, J Weisman, M Ståhle, D Wilsmann-Theis, M Wang, K Wixted, B Szilagyi, L Puig

Page s69

Poster PDF

Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial

RB Warren, C Conrad, P Foley, L Iversen, RG Langley, G Kokolakis, L Davis, V Vanvoorden, S Wiegratz, JF Merola

Page s70

Poster PDF

Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon

Page s71

Poster PDF

Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials

A Armstrong, RG Langley, KB Gordon, RB Warren, D Thaçi, L Stein Gold, L Peterson, C Madden, N Nunez Gomez, D de Cuyper, A Costanzo

Page s72

Poster PDF

Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials

Andreas Pinter, Bruce Strober, David Rosmarin, Paolo Gisondi, Veerle Vanvoorden, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Richard B Warren

Page s73

Poster PDF

Atopic Dermatitis

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis

Page s74

Poster PDF

Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Marjolein de Bruin-Weller, Jacob P Thyssen, Lisa A Beck, Eric L Simpson, Shinichi Imafuku, Mark Boguniewicz, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Petra Arlert, Amy S Paller

Page s75

Poster PDF

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials

Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan I Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis

Page s76

Poster PDF

The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy S Paller, Jonathan I Silverberg, Chih-ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric L Simpson

Page s77

Poster PDF

3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt

Page s78

Poster PDF

Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Kristian Reich, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, Andrew Blauvelt

Page s79

Poster PDF

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Amy Paller, Adelaide A Hebert, John E Jett, Philip M Brown, David S Rubenstein, Stephen C Piscitelli

Page s80

Poster PDF

Alopecia

Impact of Disease History on the Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Brett King, Wilma Bergfeld, Pawel Brzewski, Özge Aşkin, Thierry Passeron, Simaran Randhawa, Ernest Law, Roger A Edwards, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune

Page s101

Poster PDF

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Xingqi Zhang, Nina Magnolo, Masato Mizuashi, Natasha Mesinkovska, Jerry Shapiro, Fan Zhang, Urs Kerkmann, Ernest Law, Robert Wolk, Gregor Schaefer

Page s102

Poster PDF

Skin Cancer

An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis

Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee

Page s89

Poster PDF

Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis

Greg Stevens, Burkhard Jansen, Terry Arnold, James Rock, Jennifer Wood, Mark Hyde, Loren Clarke

Page s90

Poster PDF

Review of Efficacy, Cost, and Adherence of Field Therapies for Actinic Keratosis

Nathaniel Lampley III, Todd Schlesinger, Rachel Rigo, Anthony M Rossi

Page s91

Poster PDF

Long-term Follow Up of ALA 10% Gel and Red-Light Photodynamic Therapy for the Treatment of Squamous Cell Carcinoma In Situ

Paul Shim, Nathalie Zeitouni

Page s92

Poster PDF

Efficacy of red-light photodynamic therapy with 10% ALA gel in relation to the epidermal extent of atypical keratinocytes in actinic keratosis - Retrospective exploratory analysis of three pivotal phase III trials

E Bierhoff, JL Cohen, RM Szeimies, U Reinhold, T Dirschka

Page s93

Poster PDF

Photodynamic Therapy for Facial Actinic Keratosis with Aminolevulinic Acid 10% Gel, Microneedling, and Red-Light Illumination

Ziv Schwartz, Gary Goldenberg

Page s94

Poster PDF

A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC)

Matthew S Goldberg, Jennifer J Siegel, Kelli Ahmed, Sarah J Kurley, Aaron S Farberg

Page s95

Poster PDF

Performance and clinical decision-making using the prognostic 40-gene expression profile (40-GEP) test in 1,018 patients with high-risk cutaneous squamous cell carcinoma (SCC)

Jennifer J Siegel, Anesh Prasai, Aaron S Farberg, Matthew S Goldberg

Page s96

Poster PDF

The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can safely forego sentinel lymph node biopsy

Abel Jarell, Christine Bailey, Brian Martin, Peter Prieto

Page s97

Poster PDF

The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms CP-GEP at identifying patients who can safely forego sentinel lymph node biopsy

Abel Jarell, Brian Martin, Peter Prieto

Page s98

Poster PDF

A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence

Aaron S Farberg, Kelli Ahmed, Briana B Rackley, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Sarah J Kurley, Matthew S Goldberg

Page s99

Poster PDF

How Mohs surgeons utilize prognostic testing for high-risk cutaneous squamous cell carcinoma (SCC): a clinical impact study

Sarah T Arron, Alison L Fitzgerald, Jennifer J Siegel, Anesh Prasai, Briana B Rackley, Sarah J Kurley, Brent Moody

Page s100

Poster PDF

Pruritus & Prurigo Nodularis

Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study

Sonja Ständer, Elke Weisshaar, Jennifer L Parish, Jacek C Szepietowski, Adam Reich, Neil J Korman, Enoch Bortey, Thomas R Sciascia

Page s103

Poster PDF

A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Brian S Kim, Robert Bissonnette, Kristine Nograles, Catherine Munera, Nilam Shah, Alia Jebara, Joshua Cirulli, Joana Goncalves, Mark Lebwohl

Page s104

Poster PDF

Acne & Rosacea

An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris

Hilary Baldwin, Emmy Graber, Richard G Fried, Evan A Rieder, Julie C Harper, Andrew F Alexis, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s81

Poster PDF

Impact of acne on social functioning, emotional functioning, and activities of daily living among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in real-world community practices across the U.S. (PROSES Study)

Richard G Fried, Evan A Rieder, Andrew F Alexis, Hilary Baldwin, Emmy Graber, Julie C Harper, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s82

Poster PDF

Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study)

Emmy Graber, Hilary Baldwin, Julie C Harper, Linda Stein Gold, Ayman Grada, Andrew F Alexis, Adelaide A Hebert, Richard G Fried, Evan A Rieder, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Leon Kircik

Page s83

Poster PDF

Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability

Leon Kircik, Zoe D Draelos, Eric Guenin

Page s84

Poster PDF

Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants with Acne

Lawrence F Eichenfield, Linda Stein Gold, Leon Kircik, William P Werschler, Kenneth Beer, Zoe D Draelos, Emil A Tanghetti, Kim Papp, Hilary Baldwin, Edward Lain, Neil Sadick, Eric Guenin

Page s85

Poster PDF